Valuation: Defence Therapeutics Inc.

Market Cap 33.35M 23.48M 20.52M 18.86M 17.58M 2.24B 33.85M 226M 88.03M 1.1B 88.13M 86.23M 3.79B P/E 2024
-2.5x
P/E 2025 -9.9x
Enterprise Value 33.62M 23.67M 20.69M 19.02M 17.72M 2.25B 34.13M 228M 88.74M 1.11B 88.84M 86.94M 3.82B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
66.13%
Yield 2024 *
-
Yield 2025 -
1 week-13.00%
Current month-1.14%
1 month-14.71%
3 months-16.35%
6 months-36.96%
Current year-39.58%
1 week 0.41
Extreme 0.41
0.46
1 month 0.41
Extreme 0.41
0.55
Current year 0.41
Extreme 0.41
0.74
1 year 0.41
Extreme 0.41
0.93
3 years 0.41
Extreme 0.41
3.04
5 years 0.41
Extreme 0.41
8.15
10 years 0.41
Extreme 0.41
8.15
Manager TitleAgeSince
Chief Executive Officer 53 2024-09-26
Director of Finance/CFO 55 2024-12-19
Chief Tech/Sci/R&D Officer - 2024-11-24
Director TitleAgeSince
Director/Board Member 53 2020-06-01
Director/Board Member 64 2021-01-04
Director/Board Member - 2024-09-26
Date Insider Type Main position Quantity % Market Cap.
06-02Other

Director

0 0%
06-02Option

Director

150,000 0.1979%
05-31Other

Director

0 0%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-13.00%-40.41%-85.50% 23.21M
+1.70%+7.41%+2.50%+8.18% 49.92B
+0.92%+3.93%+399.71%+604.02% 40.23B
+1.89%+8.32%+26.06%-6.27% 34.55B
+2.38%+6.35%+21.25%+55.45% 33.09B
+3.96%+10.67%+8.30%+37.95% 27.51B
+2.51%+5.27% - - 17.05B
+2.58%+5.79%+73.44%+135.37% 15.92B
+0.32%+0.58%+14.00%+19.09% 13.86B
+3.30%+0.76%+90.23%+93.88% 13.52B
Average +1.96%+3.94%+66.12%+95.80% 24.57B
Weighted average by Cap. +2.07%+6.53%+90.19%+135.84%

Financials

2024 2025
Net sales - -
Net income -13.19M -9.29M -8.12M -7.46M -6.96M -884M -13.39M -89.59M -34.83M -435M -34.87M -34.12M -1.5B -3.52M -2.48M -2.17M -1.99M -1.86M -236M -3.58M -23.92M -9.3M -116M -9.31M -9.11M -400M
Net Debt 1.69M 1.19M 1.04M 956K 891K 113M 1.72M 11.48M 4.46M 55.68M 4.47M 4.37M 192M 272K 191K 167K 154K 143K 18.22M 276K 1.85M 718K 8.96M 718K 703K 30.87M
Logo Defence Therapeutics Inc.
Defence Therapeutics Inc. is a Canada-based clinical-stage biotechnology company. The Company is engaged in developing and engineering the antibody drug conjugates (ADC) products using its proprietary platform. Its principal business activity is the development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological-/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The core of its therapeutics platform is the ACCUM technology, which enables precision delivery ADCs in their intact form to target cells. The Company is focused on research, development and advancement of the main products using its Accum technology, which include ADC targeting various cancers, Anti-cancer AccuTOX program, Mesenchymal stromal cell-based vaccine (ARM-X) targeting cancer, mRNA vaccination, Cervical cancer vaccine, and Radio-immunoconjugates (RIC) targeting various cancers.
Employees
-
Date Price Change Volume
26-07-03 $0.4350 0.00% 34,200
26-07-02 $0.4350 -1.14% 38,620
26-06-30 $0.4400 0.00% 34,500